$-0.11
(Market cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-20 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
5,485,100
10 Years Aggregate
CFO
$-42.79 Mln
EBITDA
$-114.10 Mln
Net Profit
$-135.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AIkido Pharma (AIKI)
| 15.9 | -3.3 | -5.9 | -46.8 | -39.8 | -47.4 | -54.0 |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
AIkido Pharma (AIKI)
| -32.5 | -33.1 | -46.0 | -53.8 | 34.6 | -62.6 | -86.5 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AIkido Pharma (AIKI)
|
3.8 | 19.5 | 0.0 | -16.7 | -- | -16.8 | -- | 0.2 |
| 19.7 | 1,189.6 | 0.0 | -167.8 | -- | -128.7 | -- | 5.5 | |
| 26.0 | 17,122.0 | 3,722.9 | 963.8 | 40.1 | 4.5 | 18.1 | 2.8 | |
| 13.2 | 2,309.3 | 550.0 | 458.1 | -3.3 | 45.9 | 5.1 | 1.8 | |
| 5.3 | 1,121.3 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 4.6 | |
| 14.6 | 2,044.0 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.6 | |
| 12.9 | 1,158.3 | 403.3 | 22.8 | 3,081.6 | 9.1 | 410 | 4.2 | |
| 3.4 | 615.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.2 | |
| 17.3 | 406.3 | 4.7 | -109.7 | -- | -30.2 | -- | 1.3 | |
| 19.0 | 2,360.6 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.3 |
Shareholding Pattern
View DetailsAbout AIkido Pharma (AIKI)
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute... lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York. Read more
-
CEO, Principal Financial Officer, Principal Accounting Officer & Director
Mr. Anthony C. Hayes Esq.
-
CEO, Principal Financial Officer, Principal Accounting Officer & Director
Mr. Anthony C. Hayes Esq.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AIkido Pharma (AIKI)
What is the current share price of AIkido Pharma Inc (AIKI) Today?
The share price of AIkido Pharma Inc (AIKI) is $3.80 (NASDAQ) as of 22-Feb-2023 09:30 EDT. AIkido Pharma Inc (AIKI) has given a return of -39.81% in the last 3 years.
What is the current PB & PE ratio of AIkido Pharma Inc (AIKI)?
Since, TTM earnings of AIkido Pharma Inc (AIKI) is negative, P/E ratio is not available.
The P/B ratio of AIkido Pharma Inc (AIKI) is 0.25 times as on 22-Feb-2023, a 95 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of AIkido Pharma Inc (AIKI)?
The 52-week high and low of AIkido Pharma Inc (AIKI) are Rs -- and Rs -- as of 08-May-2026.
What is the market cap of AIkido Pharma Inc (AIKI)?
AIkido Pharma Inc (AIKI) has a market capitalisation of $ 20 Mln as on 22-Feb-2023. As per SEBI classification, it is a company.
Should I invest in AIkido Pharma Inc (AIKI)?
Before investing in AIkido Pharma Inc (AIKI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.